$2.57 Billion is the total value of Tekla Capital Management LLC's 187 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 75.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JNJ | Buy | Johnson & Johnson | $114,448,000 | +11.3% | 893,082 | +21.3% | 4.45% | +12.2% |
| UNH | Buy | Unitedhealth Group Incorporated | $75,396,000 | +11.8% | 352,317 | +15.2% | 2.93% | +12.7% |
| PFE | Buy | Pfizer Inc. | $72,823,000 | +106.2% | 2,051,943 | +110.4% | 2.83% | +107.9% |
| MYL | Buy | Mylan N.V.shares | $71,099,000 | +4.8% | 1,726,967 | +7.7% | 2.76% | +5.7% |
| ILMN | Buy | Illumina, Inc. | $69,718,000 | +11.7% | 294,892 | +3.2% | 2.71% | +12.6% |
| ABBV | Buy | AbbVie Inc. | $42,662,000 | +27.4% | 450,738 | +30.2% | 1.66% | +28.4% |
| MDT | Buy | Medtronic plcshares | $41,892,000 | +2.5% | 522,211 | +3.2% | 1.63% | +3.4% |
| AGN | Buy | Allergan plcshares | $41,877,000 | +23.0% | 248,836 | +19.5% | 1.63% | +24.1% |
| LLY | Buy | Eli Lilly and Company | $37,669,000 | +16.4% | 486,865 | +27.1% | 1.46% | +17.4% |
| BMY | Buy | Bristol-Myers Squibb Company | $33,252,000 | +55.4% | 525,722 | +50.6% | 1.29% | +56.7% |
| TMO | Buy | Thermo Fisher Scientific Inc. | $30,526,000 | +16.5% | 147,855 | +7.2% | 1.19% | +17.5% |
| IDXX | Buy | IDEXX Laboratories, Inc. | $29,297,000 | +41.6% | 153,076 | +15.7% | 1.14% | +42.7% |
| SRPT | Buy | Sarepta Therapeutics, Inc. | $28,044,000 | +50.7% | 378,516 | +13.2% | 1.09% | +51.9% |
| XBI | Buy | SPDR S&P Biotech ETFs&p biotech etf | $21,973,000 | +14.3% | 250,460 | +10.6% | 0.86% | +15.4% |
| ANTM | Buy | Anthem, Inc. | $20,099,000 | +98.9% | 91,482 | +103.7% | 0.78% | +100.5% |
| SAGE | Buy | Sage Therapeutics, Inc. | $20,077,000 | +79.7% | 124,650 | +83.8% | 0.78% | +81.2% |
| JAZZ | Buy | Jazz Pharmaceuticals plcshares | $18,494,000 | +39.6% | 122,482 | +24.4% | 0.72% | +40.7% |
| SGEN | Buy | Seattle Genetics, Inc. | $18,136,000 | +51.5% | 346,499 | +54.9% | 0.70% | +52.6% |
| ALNY | Buy | Alnylam Pharmaceuticals, Inc. | $15,528,000 | +6.3% | 130,376 | +13.4% | 0.60% | +7.3% |
| GSK | Buy | GlaxoSmithKline plcshares | $15,423,000 | +21.1% | 394,749 | +10.0% | 0.60% | +22.2% |
| PIRS | Buy | Pieris Pharmaceuticals, Inc. | $14,236,000 | -3.9% | 2,087,380 | +6.4% | 0.55% | -3.0% |
| ESPR | New | Esperion Therapeutics, Inc. | $13,691,000 | – | 189,287 | +100.0% | 0.53% | – |
| NKTR | New | Nektar Therapeutics | $13,231,000 | – | 124,517 | +100.0% | 0.52% | – |
| FOLD | Buy | Amicus Therapeutics, Inc. | $13,165,000 | +51.2% | 875,304 | +44.7% | 0.51% | +52.4% |
| BSX | Buy | Boston Scientific Corporation | $12,501,000 | +90.6% | 457,585 | +72.9% | 0.49% | +92.1% |
| GWPH | Buy | GW Pharmaceuticals plcads | $12,482,000 | +278.2% | 110,784 | +343.1% | 0.48% | +281.9% |
| ALKS | Buy | Alkermes plcshares | $12,182,000 | +54.5% | 210,182 | +45.9% | 0.47% | +55.9% |
| BLUE | Buy | bluebird Bio, Inc. | $11,322,000 | +35.0% | 66,308 | +40.8% | 0.44% | +36.2% |
| SYK | Buy | Stryker Corporation | $10,340,000 | +112.0% | 64,258 | +104.0% | 0.40% | +113.8% |
| GLPG | Buy | Galapagos NVsponsored adr | $9,541,000 | +91.3% | 95,635 | +79.8% | 0.37% | +93.2% |
| EW | Buy | Edwards Lifesciences Corporation | $9,247,000 | +26.0% | 66,275 | +1.8% | 0.36% | +27.2% |
| MDCO | New | The Medicines Company | $9,170,000 | – | 278,391 | +100.0% | 0.36% | – |
| ZBH | Buy | Zimmer Biomet Holdings, Inc. | $8,950,000 | -7.6% | 82,080 | +2.2% | 0.35% | -7.0% |
| HCA | Buy | HCA Healthcare, Inc. | $8,912,000 | +59.9% | 91,881 | +44.8% | 0.35% | +61.4% |
| EPZM | Buy | Epizyme, Inc. | $8,615,000 | +50.5% | 485,325 | +6.4% | 0.34% | +51.6% |
| BGNE | Buy | BeiGene, Ltd.sponsored adr | $8,315,000 | +225.2% | 49,496 | +89.1% | 0.32% | +226.3% |
| ESRX | Buy | Express Scripts Holding Company | $7,357,000 | +16.6% | 106,500 | +26.0% | 0.29% | +17.7% |
| DHR | Buy | Danaher Corporation | $7,328,000 | +419.3% | 74,847 | +392.3% | 0.28% | +427.8% |
| IONS | Buy | Ionis Pharmaceuticals, Inc. | $7,303,000 | +12.6% | 165,677 | +28.5% | 0.28% | +13.6% |
| BPMC | New | Blueprint Medicines Corporation | $6,806,000 | – | 74,221 | +100.0% | 0.26% | – |
| CRSP | New | CRISPR Therapeutics AG | $6,454,000 | – | 141,191 | +100.0% | 0.25% | – |
| AVDL | Buy | Avadel Pharmaceuticals plcsponsored adr | $5,938,000 | +16.0% | 814,588 | +30.5% | 0.23% | +17.3% |
| ISRG | Buy | Intuitive Surgical, Inc. | $5,870,000 | +317.8% | 14,218 | +269.3% | 0.23% | +322.2% |
| FGEN | New | FibroGen, Inc. | $4,819,000 | – | 104,307 | +100.0% | 0.19% | – |
| UTHR | Buy | United Therapeutics Corporation | $4,636,000 | +93.2% | 41,261 | +154.4% | 0.18% | +93.5% |
| EDIT | New | Editas Medicine, Inc. | $4,568,000 | – | 137,801 | +100.0% | 0.18% | – |
| BHVN | New | Biohaven Pharmaceutical Holding Company Ltd. | $4,185,000 | – | 162,477 | +100.0% | 0.16% | – |
| ALBO | New | Albireo Pharma, Inc. | $4,071,000 | – | 125,000 | +100.0% | 0.16% | – |
| PBYI | Buy | Puma Biotechnology, Inc. | $3,810,000 | -20.4% | 55,985 | +15.7% | 0.15% | -20.0% |
| BDX | New | Becton, Dickinson and Company | $3,739,000 | – | 17,254 | +100.0% | 0.14% | – |
| MASI | New | Masimo Corporation | $3,665,000 | – | 41,666 | +100.0% | 0.14% | – |
| ALDR | New | Alder Biopharmaceuticals, Inc. | $3,555,000 | – | 279,950 | +100.0% | 0.14% | – |
| NTLA | New | Intellia Therapeutics, Inc. | $3,530,000 | – | 167,381 | +100.0% | 0.14% | – |
| Buy | Trillium Therapeutics Inc. | $3,372,000 | +2.6% | 468,399 | +4.1% | 0.13% | +3.1% | |
| AFMD | Buy | Affimed N.V. | $3,340,000 | +82.8% | 1,805,324 | +28.5% | 0.13% | +85.7% |
| RMD | New | ResMed Inc. | $3,330,000 | – | 33,819 | +100.0% | 0.13% | – |
| PTLA | New | Portola Pharmaceuticals, Inc. | $2,939,000 | – | 89,978 | +100.0% | 0.11% | – |
| PHG | Buy | Koninklijke Philips N.V.ny registry shares | $2,886,000 | +9.1% | 75,335 | +7.6% | 0.11% | +9.8% |
| BAX | New | Baxter International Inc.sponsored adr | $2,599,000 | – | 39,965 | +100.0% | 0.10% | – |
| ARRY | New | Array BioPharma Inc. | $2,547,000 | – | 156,056 | +100.0% | 0.10% | – |
| TXMD | Buy | TherapeuticsMD, Inc. | $2,283,000 | -10.0% | 468,769 | +11.6% | 0.09% | -9.2% |
| QTNT | Buy | Quotient Limitedshares | $2,084,000 | +101.0% | 442,461 | +111.2% | 0.08% | +102.5% |
| CHRS | Buy | Coherus BioSciences, Inc. | $2,000,000 | +152.5% | 181,023 | +101.1% | 0.08% | +151.6% |
| ABMD | New | ABIOMED, Inc. | $1,896,000 | – | 6,514 | +100.0% | 0.07% | – |
| PTGX | Buy | Protagonist Therapeutics, Inc. | $1,882,000 | +9.2% | 219,042 | +164.5% | 0.07% | +10.6% |
| TLGT | New | Teligent, Inc. | $1,853,000 | – | 551,429 | +100.0% | 0.07% | – |
| SNN | Buy | Smith & Nephew plcsponsored adr | $1,684,000 | +19.7% | 44,148 | +9.9% | 0.06% | +20.4% |
| STE | New | STERIS plcshares | $1,551,000 | – | 16,612 | +100.0% | 0.06% | – |
| NLNK | New | NewLink Genetics Corporation | $1,486,000 | – | 205,026 | +100.0% | 0.06% | – |
| RVNC | Buy | Revance Therapeutics, Inc. | $1,335,000 | +15.9% | 43,329 | +34.5% | 0.05% | +18.2% |
| AKBA | New | Akebia Therapeutics, Inc. | $1,266,000 | – | 132,849 | +100.0% | 0.05% | – |
| HOLX | New | Hologic, Inc. | $730,000 | – | 19,546 | +100.0% | 0.03% | – |
| ARNA | New | Arena Pharmaceuticals, Inc. | $665,000 | – | 16,827 | +100.0% | 0.03% | – |
| PTCT | New | PTC Therapeutics, Inc. | $658,000 | – | 24,299 | +100.0% | 0.03% | – |
| TFX | New | Teleflex Incorporated | $633,000 | – | 2,482 | +100.0% | 0.02% | – |
| VAR | New | Varian Medical Systems, Inc. | $621,000 | – | 5,065 | +100.0% | 0.02% | – |
| FMI | New | Foundation Medicine, Inc. | $500,000 | – | 6,353 | +100.0% | 0.02% | – |
| EIGR | New | Eiger BioPharmaceuticals, Inc. | $452,000 | – | 45,854 | +100.0% | 0.02% | – |
| NCNA | New | NuCana plcsponsored adr | $464,000 | – | 24,536 | +100.0% | 0.02% | – |
| ASND | New | Ascendis Pharma A/Ssponsored adr | $406,000 | – | 6,214 | +100.0% | 0.02% | – |
| MTEM | New | Molecular Templates, Inc. | $423,000 | – | 52,891 | +100.0% | 0.02% | – |
| ADMS | New | Adamas Pharmaceuticals, Inc. | $399,000 | – | 16,699 | +100.0% | 0.02% | – |
| NTUS | New | Natus Medical Incorporated | $381,000 | – | 11,335 | +100.0% | 0.02% | – |
| AGIO | New | Agios Pharmaceuticals, Inc. | $230,000 | – | 2,810 | +100.0% | 0.01% | – |
| JNCE | New | Jounce Therapeutics, Inc. | $226,000 | – | 10,127 | +100.0% | 0.01% | – |
| TBPH | New | Theravance Biopharma, Inc. | $196,000 | – | 8,083 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.